Skip to main content
Figure 4 | Arthritis Research & Therapy

Figure 4

From: Intravenous administration of anti-vascular endothelial growth factor humanized monoclonal antibody bevacizumab improves articular cartilage repair

Figure 4

Chondromodulin (ChM)-I and vascular endothelial growth factor (VEGF) localized in cartilage at 1 month after surgery. (a, c) The defect treated with bevacizumab. (b, d) The defect in the control. (a) In the bevacizumab group, ChM-I immunostaining is detected in the interterritorial matrix of the remodeling site. (b) In the control group, ChM-I immunostaining is not detected in the remodeling site. (c, d) In both groups, VEGF immunostaining is detected in the remodeling site of the reparative cells. Bars, 100 μm in (a) and (b) and 25 μm in (c) and (d).

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us